Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, March 23, 2011 - Astellas Pharma Inc. (“Astellas”, TSE: 4503) expresses its deepest sympathy for those who have lost their lives and been displaced by the Tohoku Earthquake, which...
Read more about Astellas Assesses the Impact of the Tohoku Earthquake (2nd Notice)
Tokyo, March 17, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it has exercised a buy-out option to acquire all of...
Read more about Astellas Pharma Inc.: Exercises Buy-Out Option for Perseid
Tokyo, March 16, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that OSI Pharmaceuticals, Inc. (a subsidiary of Astellas),...
Read more about OSI, Genentech, Pfizer and Teva Reach Settlement Agreement in Tarceva® Patent Case
Tokyo, March 15, 2011 - Astellas Pharma Inc. (“Astellas”, TSE: 4503) is currently assessing the impact of the Tohoku Earthquake upon its various facilities and provides details of current...
Read more about Astellas Assesses the Impact of the Tohoku Earthquake
Follow us
